Celldex Therapeutics Inc. (NASDAQ:CLDX) shares were down 1.8% on Thursday . The company traded as low as $4.34 and last traded at $4.42, with a volume of 1,675,234 shares changing hands. The stock had previously closed at $4.50.

CLDX has been the subject of a number of research analyst reports. Roth Capital reiterated a “buy” rating and set a $7.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, April 19th. Jefferies Group lifted their price target on Celldex Therapeutics to $5.00 and gave the company a “hold” rating in a research report on Friday, August 5th. Wedbush reiterated a “neutral” rating and set a $3.00 price target on shares of Celldex Therapeutics in a research report on Friday, May 6th. Finally, Cowen and Company reiterated an “outperform” rating and set a $12.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, June 7th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $10.75.

The firm has a 50 day moving average price of $4.57 and a 200-day moving average price of $4.89. The stock’s market capitalization is $448.43 million.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.02. The firm earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. During the same period in the prior year, the company posted ($0.33) EPS. The firm’s revenue was down 36.4% compared to the same quarter last year. Analysts expect that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Celldex Therapeutics stock. Rhumbline Advisers raised its stake in Celldex Therapeutics Inc. (NASDAQ:CLDX) by 4.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 108,426 shares of the biopharmaceutical company’s stock after buying an additional 5,110 shares during the period. Rhumbline Advisers owned 0.11% of Celldex Therapeutics worth $1,700,000 at the end of the most recent reporting period.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.